logo
Family of Penn Hills officer who died by suicide after Lasik surgery receives letter from FDA

Family of Penn Hills officer who died by suicide after Lasik surgery receives letter from FDA

CBS News3 days ago
A young Pittsburgh-area police officer died by suicide and pointed to Lasik eye surgery complications as the reason. Now his Penn Hills family is demanding industry accountability.
Ryan Kingerski's family members said the 26-year-old's Lasik eye surgery led to unbearable pain. They say if doctors and industry leaders highlighted or even conveyed the real, much higher complication numbers, patients would be better educated about the risks. They believe the industry is trying to downplay complications and silence people like their late son.
FDA sends letter to Ryan Kingerski's family
In an interview with KDKA-TV earlier this year, mom Stefanie Kingerski described her son Ryan as "witty, charming, smart."
But the dedicated Penn Hills police officer died by suicide after struggling with debilitating side effects following Lasik, which is an elective eye surgery.
"He kept saying about how bad the pain in his head was. He had a terrible headache and wasn't able to focus, and the vision and the blurriness and everything else," dad Tim Kingerski previously explained.
Now Tim and Stefanie Kingerski are fighting for industry accountability, sharing with KDKA Investigates a new response letter they say they received from the Food and Drug Administration, signed by the FDA's consumer team. They say it proves acknowledgement of what they call a gross underreporting of adverse side effects.
It says the FDA inspector "has been following these Laser Lasik incidences for several years. He explained there is under-reporting by the Ophthalmic Clinics because they are not submitting the required patient injuries to the FDA."
The letter also says the FDA is "actively looking into sending out a 'warning notice' to the public about the risks" of Lasik.
FDA adviser who approved Lasik says he regrets it
"I tell people that ask me, and even if they don't ask, it's 'trust but verify.' If they say it's 1%, go look it up, go find out what is the actual rate," said retired FDA adviser Dr. Morris Waxler.
Waxler voted to approve Lasik three decades ago, but now he says he regrets it and is one of Lasik's biggest critics after his independent review of the data.
"They'll make a long list if they provide any information about informed consent. Provide a long list of things that could happen, but they will not provide actual percentages because they know the percentages are really high. They're 10% to 20% to 30%, some as high as 75%, depending on what you're measuring."
The FDA warns on its website that some patients may lose vision and develop debilitating visual symptoms, adding that the long-term safety and effectiveness of Lasik surgery is not known.
Still, supporters of Lasik tout a 1% complication rate.
"And all I can do is provide the information, and they can look it up. And you can ask the surgeon, 'Well, why don't you cite that study? Why are you ignoring that study? Why are you not pointing this out? Is there something wrong with those studies? Why have you ignored this whole body of literature?' So you need to ask them questions," Waxler said.
Red flags for any elective procedure include you feel like you're receiving a sales pitch, a surgeon promises perfection, there's pressure to make a decision quickly, side effects are not highlighted or minimized and it feels more like a business transaction than medical care.
Waxler points out Lasik is very attractive to young people, public servants, like police officers like Ryan, and military members.
U.S. congressman talking with FDA
The Kingerski family said Congressman Chris Deluzio is now looking into this, given his military background, and hoping to find answers, as well.
"Congressman Deluzio's office is engaging with the FDA to see what can be done to avoid terrible tragedies like Officer Kingerski's from happening in the future. Our brave cops have hard enough jobs; nobody should worry about losing their life after something like this," his spokesperson said in a statement.
KDKA-TV also reached out directly to the FDA and was told, "The FDA does not discuss possible or ongoing investigations."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas
Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas

Yahoo

time42 minutes ago

  • Yahoo

Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas

Abbott Laboratories (NYSE:ABT) is one of the high profit margin stocks to buy now. On June 19, Beta Bionics Inc. (NASDAQ:BBNX) announced its plan to integrate its iLet Bionic Pancreas automated insulin delivery/AID system with Abbott's future dual glucose-ketone sensor in the US. The collaboration aims to enhance real-time decision-making support for individuals with diabetes. The iLet Bionic Pancreas received FDA clearance in May 2023 and is distinguished as the first and only AID system that autonomously makes 100% of insulin dosing decisions. This eliminates the need for carb counting or manual insulin correction calculations for users, though they still need to be 'carb aware.' The system currently supports Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor, and the new agreement deepens the ongoing partnership between Beta Bionics and Abbott. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The new dual sensor is currently under development and is built on the same form factor as Abbott's FreeStyle Libre 3 Plus and will continuously monitor both glucose and ketone levels. Ketone monitoring is a crucial advancement as it can help detect early signs of diabetic ketoacidosis, which is a serious complication of diabetes. Abbott's dual glucose-ketone sensor has received FDA breakthrough device designation. Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells health care products. Beta Bionics Inc. (NASDAQ:BBNX) is a commercial-stage medical device company. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies
BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies

Yahoo

time2 hours ago

  • Yahoo

BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies

BrightSpring Health Services Inc. (NASDAQ:BTSG) is one of the best new stocks to buy now. On June 18, BrightSpring Health Services announced that its specialty pharmacy, called Onco360, has been chosen as the national pharmacy partner for several newly approved therapies. These innovative treatments target advanced cancers and rare genetic disorders. BrightSpring delivers care and clinical solutions to 400,000+ customers, clients, and patients daily across all 50 states. Onco360 will provide access, education, data, and expert support for patients suffering from advanced ovarian and lung cancers, as well as neurofibromatosis type 1. A medical technician using surgical robotics to perform minimally-invasive urologic surgery in an operating room. Onco360 has been selected as a pharmacy partner for the following specific medication therapies: GOMEKLI, which is approved for adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas/PN not suitable for complete resection; AVMAPKI FAKZYNJA CO-PACK, which is approved for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer/LGSOC who have received prior systemic therapy; and IBTROZI, which is approved for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US that operates through 2 segments: Pharmacy Solutions and Provider Services. Onco360 is a national, independent Oncology Pharmacy and clinical support services company. While we acknowledge the potential of BTSG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Waystar Study Highlights AI's Critical Role, Proven ROI in Healthcare Payments
Waystar Study Highlights AI's Critical Role, Proven ROI in Healthcare Payments

Yahoo

time2 hours ago

  • Yahoo

Waystar Study Highlights AI's Critical Role, Proven ROI in Healthcare Payments

Waystar Holding Corp. (NASDAQ:WAY) is one of the best new stocks to buy now. On June 23, Waystar announced the findings of a commissioned study conducted by Forrester Consulting. The study is titled 'AI in Healthcare Payments Software: A Strategic Imperative,' and revealed that AI is becoming increasingly critical in revenue cycle management/RCM due to its proven impact and measurable ROI. The research shows acceleration in AI adoption within healthcare. 82% of healthcare leaders now consider AI an integral part of their RCM operations, with 70% identifying it as a top organizational priority. The study also found that AI is delivering improvements in key revenue cycle metrics, such as a 13% to 37% improvement in high-impact areas such as claim accuracy, denial prevention, workforce efficiency, and payment speed. A medical professional with a patient explaining the effects of neurostimulation treatments. Trust in AI is growing, with 60% of decision-makers reporting increased confidence since implementing AI. ~ 70% of healthcare leaders view AI as a high or critical organizational priority, and 60% plan to increase their AI investment. The study is based on responses from 300+ healthcare leaders and highlights a preference for existing RCM software partners when it comes to AI capabilities. Waystar serves ~30,000 clients and represents over 1 million distinct providers, including 16 of the top 20 institutions on the US News Best Hospitals list. Waystar Holding Corp. (NASDAQ:WAY) develops a cloud-based software solution for healthcare payments. While we acknowledge the potential of WAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store